Danaher (DHR) vs Myriad Genetics (MYGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Danaher (DHR) has outperformed Myriad Genetics (MYGN) over the past year, gaining 6.1% versus a loss of 45.0%. Over five years, DHR leads with a -18.6% price change compared with -86.8% for MYGN. Danaher is the larger company by market cap ($152.87 billion vs $401.7 million), about 380.5 times the size.
Danaher pays a dividend yielding 0.66%, while Myriad Genetics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DHR | MYGN |
|---|---|---|
| Share price | $217.46 | $4.20 |
| Market cap | $152.87B | $401.73M |
| 1-day change | -0.47% | -1.87% |
| YTD return | -5.01% | -31.71% |
| 1-year return | +6.10% | -45.03% |
| 5-year return | -18.61% | -86.77% |
| P/E ratio (TTM) | 38.76 | — |
| Forward P/E | 23.39 | — |
| EPS (TTM) | $5.61 | $-1.18 |
| Dividend yield | 0.66% | 0.00% |
| Annual dividend | $1.44 | $0.00 |
| Revenue (latest FY) | $24.57B | — |
| Revenue growth (YoY) | +2.90% | — |
| Net income (latest FY) | $3.61B | — |
| Gross margin | 59.11% | — |
| Operating margin | 19.09% | — |
| Net margin | 14.71% | — |
| 52-week high | $242.80 | $8.59 |
| 52-week low | $160.93 | $2.74 |
| Distance from 52-week high | -10.44% | -51.11% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +9.93% | -6.90% |
| Average volume | 4.74M | 2.02M |
| Shares outstanding | 702.99M | 95.65M |
| Employees | 58,000 | 2,700 |
| Sector | Industrials | Health Care |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Danaher is about 380.5 times larger than Myriad Genetics by market value ($152.87B vs $401.73M).
- DHR has outperformed MYGN by 51.1 percentage points over the past year.
- The two companies sit in different sectors: Danaher in Industrials and Myriad Genetics in Health Care.
About Danaher
DHR stock →Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments.
Industrials · Industrial Machinery/Components · 58,000 employees
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
DHR vs MYGN FAQ
Which is bigger, Danaher or Myriad Genetics?
Danaher (DHR) is larger, with a market capitalization of $152.87B compared with $401.73M for Myriad Genetics (MYGN).
Which stock has performed better over the past year, DHR or MYGN?
DHR returned +6.10% over the past 12 months, compared with -45.03% for MYGN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Danaher or Myriad Genetics?
Danaher pays a dividend yielding 0.66%, while Myriad Genetics does not currently pay a regular dividend.
Are Danaher and Myriad Genetics in the same industry?
No. Danaher is in the Industrials sector, while Myriad Genetics is in Health Care.